NCR3 and lymphoma: In summary, this retrospective study showed the importance of the day 100 inhibitory KIR2DL2 and activating NKp30 NK cells with regard to understanding how the host immunity (NK cells) could improve survival in lymphoma patients treated with APBHSCT.